Genetics Genotype Licensing 
The Pharma Data
NOVEMBER 2, 2020
ONWARD is investigating Adial’s lead drug candidate, AD04, as a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes related to the serotonin transporter and receptor genes. Key ONWARD highlights include: All 25 planned investigative sites are active.
XTalks
APRIL 24, 2023
Approximately 72 percent of rare diseases are genetic, and around 70 percent of rare genetic diseases emerge in childhood. One substantial obstacle is from the additional regulatory requirements of gene therapies containing genetically modified organisms (GMOs). Rare diseases can often be progressive, chronic and fatal.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 9, 2020
Vigil’s pipeline strategy is to target these diseases by combining a high-level understanding of microglia physiology, disease genotyping, and patient phenotyping to identify specific genetic variations associated with microglial dysfunction. which will remain a key shareholder. SciNeuro Pharmaceuticals.
The Pharma Data
DECEMBER 9, 2020
The aim of the research will be to create a TGS IVD platform by optimizing a multi-layer approach encompassing the initial sample and library preparation, state-of-the-art sequencing technologies and improved genotyping procedures. Amolyt has also acquired an option to license the identified candidates for future clinical development.
XTalks
MARCH 26, 2025
XTALKS WEBINAR: Biomarker Solutions for Steatotic Liver Disease: Enabling Better Insights into MASH/MASLD Biology Live and On-Demand: Thursday, May 29, 2025 , at 11am EDT (4pm BST / UK) Register for this free webinar to discover the impact of genetic markers on the severity and treatment of MASH/MASLD. Net loss for Q4 was $20.2
Expert insights. Personalized for you.
52 
Let's personalize your content